B

BioMarin Pharmaceutical Inc. (BMRN)

NMS – Real vaqt narxi. Valyuta: USD

52.88

+0.30 (0.57%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

B

BioMarin Pharmaceutical Inc. (BMRN)

NMS – Real vaqt narxi. Valyuta: USD

52.88

+0.30 (0.57%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026.

05.05.2026

BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised

BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.

05.05.2026

BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript

05.05.2026

Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

04.05.2026

BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago.

04.05.2026

BioMarin Reports First Quarter 2026 Financial and Operating Results

First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD® and POMBILITI® + OPFOLDA® to BioMarin's Portfolio Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

02.05.2026

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia Researchers will present additional data from studies of VOXZOGO for hypochondroplasia, ahead of pivotal topline Phase 3 data expected in the first half of 2026 SAN RAFAEL, Calif., May 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new research from studies of VOXZOGO ® (vosoritide) in children with achondroplasia demonstrating positive impact on important health indicators, including arm span and bone density.

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

BioMarin Reports First Quarter 2026 Financial and Operating Results

First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD® and POMBILITI® + OPFOLDA® to BioMarin's Portfolio Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

02.05.2026

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia Researchers will present additional data from studies of VOXZOGO for hypochondroplasia, ahead of pivotal topline Phase 3 data expected in the first half of 2026 SAN RAFAEL, Calif., May 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new research from studies of VOXZOGO ® (vosoritide) in children with achondroplasia demonstrating positive impact on important health indicators, including arm span and bone density.

27.04.2026

BioMarin Completes Acquisition of Amicus Therapeutics

Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to Provide Updated FY 2026 Guidance During its First Quarter Earnings Call, May 4, 2026 SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion.

21.04.2026

BioMarin Announces Board Leadership Transition

Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif.

Search stocks

BioMarin Pharmaceutical Inc. (BMRN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioMarin Pharmaceutical Inc. (BMRN)

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised

BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

Videolar

No Data

Press-relizlar

BioMarin Reports First Quarter 2026 Financial and Operating Results

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

BioMarin Completes Acquisition of Amicus Therapeutics

BioMarin Announces Board Leadership Transition